BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI): Poised in the Future of Oncology with Cutting-Edge Treatments

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company at the forefront of research and development of innovative treatments in the field of immuno-oncology. With cancer being the second leading cause of death globally, the company focuses on harnessing antitumor virotherapies and patented technologies designed to protect and potentiate the virotherapy during administration to combat cancer more effectively and with fewer side effects. The company’s approach includes a systemic platform using extracellular enveloped viruses and an intratumoral platform utilizing stem cells to protect the therapy from the body’s immune system during administration. Calidi’s pipeline includes promising therapies such as RTNova, targeting lung and metastatic cancers, SuperNova, targeting solid tumors such as head and neck, triple-negative breast cancer and soft tissue sarcoma, as well as NeuroNova, designed for patients with glioblastoma and other high-grade gliomas. These cutting-edge therapies aim to address critical gaps in current cancer treatments. As the global cancer burden continues to grow, Calidi is poised to play a pivotal role in shaping the future of oncology drug development.

To view the full article, visit https://ibn.fm/wtmUF

About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, visit the company’s website at www.calidibio.com.

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://ibn.fm/CLDI